Antibody developability: How to effectively navigate challenges and opportunities in predicting antibody properties?
Explore the insights from the expert panel about the current landscape, challenges, and transformative potential of AI/ML technologies in supporting antibody developability.
Evaluating protein-protein interactions in AF3 predicted complexes: a PD-1 case study
Can protein-protein complex models generated by AF3 effectively serve as starting points for predicting protein-protein interactions and identifying binding hotspots, thus facilitating drug design?
Using our software, 3decision®, we evaluated the accuracy of the AF3 models using Programmed cell death protein 1 (PD-1) complexes as a case study.
Leverage Experimental and in Silico 3D Protein Structures to Accelerate SBDD Projects
Gaining structural insights rapidly at the onset of a Structure-Based Drug Discovery project is key to driving the development of novel compounds. In this article, we illustrate the structure registration capabilities of 3decision® through a use case reproducing the identification of next-generation RXR targeting compounds.
How to best exploit 3D protein structures for ideation in SBDD
Explore the insights from industry experts on how to manage vast 3D protein structures to facilitate new design ideas in SBDD
Understanding selectivity of CLK kinase inhibitors: structural insights with 3decision®
Gain valuable insights into the selectivity of CLK kinase inhibitors with 3decision®. In this use case, we will show you the data sets preparation and binding mode analysis of the CLK kinase inhibitors’ using some of the 3decision’s cool features adapted to this specific scientific use case.
The impact of AlphaFold in drug discovery and emerging ML-methods
Following our Discngine Labs event and discussion with scientists in early drug discovery, we have summarized insights and experiences of the community on how they use AlphaFold technology to make it more suitable for drug discovery projects.
Discngine Labs: The future of Cryo-EM in Pharma
Where are we with Cryo-EM in Pharma?
Read the key takeaway messages from the Discngine Labs roundtable discussion with the domain experts from ThermoFisher Scientific, Sanofi, Boehringer Ingelheim and Nanoimaging Services, hosted by Gabriella Jonasson, PhD.
The future of Cryo-EM in Pharma [event highlights]
Industry experts shared their experience with the application of the Cryo-EM structures in their drug discovery projects in our Discngine Labs event. Have a look at the key take-aways and access the recording
Starting with 3decision®: exploration of Ikaros protein family – a molecular glue use case
In this use case, we will show you the structural differences between Helios and its family members that aided the design of molecular glue. We used some of 3decision’s cool features adapted to this specific scientific use case.
Five advantages of 3decision AWS Quick Start for pharma and biotech
Quick, Flexible and Secure are just some of the advantages of 3decision AWS Quick Start for pharma and biotech. Learn more about how you can benefit from streamlined deployment of 3decision on Amazon Web Services (AWS) cloud from our cloud expert Alexandre Gillet.
Confo Therapeutics Selects Discngine’s 3decision® Platform to Leverage the Full Potential of GPCR Structures Towards the Development of Novel Therapeutics
Discngine and Confo Therapeutics are starting strategic collaboration to enhance GPCR drug discovery. Companies aim to further collaborate on the future development of 3decision®.
![Efficient biomolecular structural data handling and analysis [Event highlights]](https://images.squarespace-cdn.com/content/v1/64ef89ef638a126e29aba776/1708556776234-ENM0CV7KOOYVLB16TOTN/maxresdefault.jpg)
Efficient biomolecular structural data handling and analysis [Event highlights]
After officially announcing the partnership, Discngine and Chemaxon organized a joint event to elaborate on technical and scientific opportunities coming from joint efforts.
Discngine partners up with ChemAxon to enhance its 3decision® platform for innovative structure-driven drug discovery
Integrating several of ChemAxon’s cheminformatics and biologics software components into 3decision will expand its capabilities to work on larger biological entities, in addition to the already available features for proteins and small molecules. The registration and visualization of biological entries, like antibodies or peptides, efficient data mining, and advanced analytical capabilities will be accessible.
5 fast-growing techniques in structural biology and their impact on drug discovery
Get to know the latest advances of five structural biology techniques and how how they impact structure-based drug discovery
EVENT HIGHLIGHTS: Structure- and ligand-based analysis - How to combine the best of two worlds for driving compound design
How can you be more efficient in deciding what compound to make next?
Read the key takeaway messages from the BAGIM panel discussion with experts from AstraZeneca and Novartis, hosted by Gabriella Jonasson, PhD.
Structure-based compound design for dihydroorotate dehydrogenase - how to leverage protein-ligand interaction patterns for scaffold hopping idea generation
Through this usecase you will get to know how to find novel chemical entities in early drug discovery using 3decision protein-ligand interaction-based search. As an example, we performed a scaffold optimization of an active compound co-crystallized with the malaria target DHODH.
